sCD40L Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 169 amino acids (113-261a.a.) and having a molecular mass of 18.3kDa.sCD40L is fused to a 20 amino acid His tag at N-Terminus and purified by proprietary chromatographic techniques.
sCD40L Human, His Active
目录号: GP26070纯度: >98%
sCD40L Human Recombinant produced in E
| 规格 | 价格 | 库存 | 数量 | 操作 |
|---|---|---|---|---|
| 2μg | ¥840.00 | 现货 | 1 | |
| 10μg | ¥2,030.00 | 现货 | 1 | |
| 100μg | ¥16,800.00 | 现货 | 1 |
电话: 400-920-5774Email: sales@glpbio.cn
文献被引
本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
Nature641, 529–536 (2025)
Nature628, 630–638 (2024)
Nature632, 686–694 (2024)
Nature618, 1017–1023 (2023)
Nature610, 366–372 (2022)
Cell187(9):2288-2304 (2024)
Cell183(7):1867-1883 (2020)
Science388(6745) (2025)
Science387(6739) (2025)
Science387(6734) (2025)
Cell Research35, 97–116 (2025)
Cell Research34, 683–706 (2024)
Cell Research33, 273–287 (2023)
Cell Research33, 546–561 (2023)
Cell Research33, 904–922 (2023)
Cell Research31, 1291–1307 (2021)
产品描述 Description
产品文档 Product Documents
Purity:>98%
Product Data
Purity
Greater than 95.0% as determined by SDS-PAGE.
Source
Escherichia Coli.
Physical Appearance
Sterile Filtered colorless solution.
Shipping Condition
withIcePacks
Synonyms
CD40 ligand, CD154, CD40L, gp39, hCD40L, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MQKGDQNPQI AAHVISEASS KTTSVLQWAE KGYYTMSNNL VTLENGKQLT VKRQGLYYIY AQVTFCSNRE ASSQAPFIAS LCLKSPGRFE RILLRAANTH SSAKPCGQQS IHLGGVFELQ PGASVFVNVT DPSQVSHGTG FTSFGLLKL
Stability
Store at 4буC if entire vial will be used within 2-4 weeks. Store, frozen at -20буC for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles.
Biological Activity
Measured by its binding ability in a functional ELISA with Human CD40/TNFRSF5.
Formulation
sCD40L protein (0.5mg/ml) contains 20mM Tris-HCl buffer (pH 8.0), 0.2M NaCl, 1mM DTT and 40% glycerol.
